BRPI0415288B8 - composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino - Google Patents
composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalinoInfo
- Publication number
- BRPI0415288B8 BRPI0415288B8 BRPI0415288A BRPI0415288A BRPI0415288B8 BR PI0415288 B8 BRPI0415288 B8 BR PI0415288B8 BR PI0415288 A BRPI0415288 A BR PI0415288A BR PI0415288 A BRPI0415288 A BR PI0415288A BR PI0415288 B8 BRPI0415288 B8 BR PI0415288B8
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline
- isobutanoyloxyethoxy
- aminomethyl
- carbonyl
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto a invenção refere-se a uma forma cristalina de um análogo de ácido (gama)-aminobutírico e a métodos para a sua fabricação.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51128703P | 2003-10-14 | 2003-10-14 | |
US60/511287 | 2003-10-14 | ||
PCT/US2004/033979 WO2005037784A2 (en) | 2003-10-14 | 2004-10-14 | Crystalline form of gamma-aminobutyric acid analog |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0415288A BRPI0415288A (pt) | 2006-12-19 |
BRPI0415288B1 BRPI0415288B1 (pt) | 2019-05-14 |
BRPI0415288B8 true BRPI0415288B8 (pt) | 2021-05-25 |
Family
ID=34465215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0415288A BRPI0415288B8 (pt) | 2003-10-14 | 2004-10-14 | composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino |
Country Status (23)
Country | Link |
---|---|
US (10) | US8026279B2 (pt) |
EP (1) | EP1677767B1 (pt) |
JP (2) | JP4308263B2 (pt) |
KR (1) | KR101096480B1 (pt) |
CN (1) | CN1867322B (pt) |
AT (1) | ATE516801T1 (pt) |
AU (1) | AU2004282192B2 (pt) |
BR (1) | BRPI0415288B8 (pt) |
CA (1) | CA2541752C (pt) |
DK (1) | DK1677767T3 (pt) |
ES (1) | ES2368916T3 (pt) |
HK (1) | HK1090850A1 (pt) |
IL (2) | IL174600A (pt) |
MX (1) | MXPA06004088A (pt) |
NO (1) | NO338275B1 (pt) |
NZ (1) | NZ546381A (pt) |
PL (1) | PL1677767T3 (pt) |
PT (1) | PT1677767E (pt) |
RU (1) | RU2412162C2 (pt) |
SG (1) | SG147437A1 (pt) |
SI (1) | SI1677767T1 (pt) |
WO (1) | WO2005037784A2 (pt) |
ZA (1) | ZA200602722B (pt) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
NZ545884A (en) * | 2003-09-11 | 2010-01-29 | Xenoport Inc | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs |
KR101157436B1 (ko) * | 2003-09-17 | 2012-07-05 | 제노포트 인코포레이티드 | Gaba 유사체의 전구약물을 이용한 하지불안 증후군의치료 또는 예방 |
ES2368916T3 (es) * | 2003-10-14 | 2011-11-23 | Xenoport, Inc. | Forma cristalina de un análogo del ácido gamma-aminobutírico. |
US20050209319A1 (en) * | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
CA2584338C (en) | 2004-11-04 | 2013-08-06 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
ES2345784T3 (es) * | 2005-06-20 | 2010-10-01 | Xenoport, Inc. | Profarmacos de aciloxialquilcarbamato del acido tranexamico y uso de los mismos. |
WO2008073257A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
TWI369982B (en) * | 2007-01-11 | 2012-08-11 | Xenoport Inc | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
WO2009061934A1 (en) * | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
TW201014818A (en) * | 2008-06-24 | 2010-04-16 | Teva Pharma | Processes for preparing prodrugs of gabapentin and intermediates thereof |
WO2010003046A2 (en) * | 2008-07-02 | 2010-01-07 | Teva Pharmaceutical Industries Ltd. | Gabapentin enacarbil salts and processes for their preparation |
WO2010017504A1 (en) * | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
WO2010017498A1 (en) | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing n-hydroxysuccinimidyl carbonates |
WO2010063002A2 (en) | 2008-11-26 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation and purification of gabapentin enacarbil |
US20100160666A1 (en) * | 2008-12-23 | 2010-06-24 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin enacarbil intermediate |
WO2010101115A1 (ja) * | 2009-03-02 | 2010-09-10 | アステラス製薬株式会社 | 固形製剤の包装体 |
NZ594648A (en) * | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
JP5580345B2 (ja) * | 2009-03-06 | 2014-08-27 | ゼノポート,インコーポレイティド | 高充填量のガバペンチンプロドラッグを有する経口剤形 |
WO2011028234A1 (en) * | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
WO2011091164A1 (en) | 2010-01-22 | 2011-07-28 | Xenoport, Inc. | Oral dosage forms having a high loading of a tranexamic acid prodrug |
WO2011133675A1 (en) * | 2010-04-21 | 2011-10-27 | Teva Pharmaceutical Industries Ltd. | Gabapentin enacarbil compositions |
WO2013008182A1 (en) * | 2011-07-10 | 2013-01-17 | Mahesh Kandula | Prodrugs of gaba analogs |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
CA2872975A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
WO2013168019A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neuropathic pain |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
SG11201407322QA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
EP2852570B1 (en) | 2012-05-23 | 2020-04-22 | Cellixbio Private Limited | Composition for the treatment of inflammatory bowel disease |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
SG11201407325YA (en) | 2012-09-08 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammation and lipid disorders |
US20150158809A9 (en) | 2013-02-26 | 2015-06-11 | Xenoport, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CA2967908C (en) | 2014-09-29 | 2020-11-17 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
AU2014414316B2 (en) | 2014-10-27 | 2020-04-09 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
RU2739192C1 (ru) * | 2020-06-18 | 2020-12-21 | федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Способ лечения абстинентного синдрома, с целью превенции развития психоза, у лиц с зависимостью от синтетических агонистов рецепторов гамма-аминомасляной кислоты: бутиролактона, 1,4-бутандиола |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
JPS62258337A (ja) | 1986-04-30 | 1987-11-10 | Kuraray Co Ltd | 4−ヒドロキシ−2,4,6−トリメチル−2,5−シクロヘキサジエン−1−オンの精製法 |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
US5084169A (en) | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
SG48288A1 (en) | 1992-05-20 | 1998-04-17 | Univ Northwestern | Gaba and l-glutamic acid analogs for antiseizure treatment |
KR19990082349A (ko) | 1996-02-07 | 1999-11-25 | 로즈 암스트롱 | 제약학적 제제로서 신규한 시클릭 아미노산 |
HU224720B1 (en) | 1996-03-14 | 2006-01-30 | Warner Lambert Co | Novel substituted cyclic amino acid derivatives use as pharmaceutical agents |
EP0888285B1 (en) | 1996-03-14 | 2001-12-12 | Warner-Lambert Company | Novel bridged cyclic amino acids as pharmaceutical agents |
WO1998003167A1 (en) | 1996-07-24 | 1998-01-29 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
DE69737719D1 (de) | 1996-10-23 | 2007-06-21 | Warner Lambert Co | Substituierte gamma-aminobuttersäurederivate als arzneimittel |
WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
CU23048A3 (es) | 1997-10-27 | 2005-06-24 | Warner Lambert Co | Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos |
AU759619B2 (en) | 1997-12-16 | 2003-04-17 | Warner-Lambert Company | Novel amines as pharmaceutical agents |
DE69826151T2 (de) | 1997-12-16 | 2005-01-27 | Warner-Lambert Co. Llc | 1-substituierte-1-aminomethyl-cycloalkan derivate (= gabapentin analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen |
HUP0100069A3 (en) | 1997-12-16 | 2002-04-29 | Warner Lambert Co | 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders |
US6605610B1 (en) | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
EP1047414A1 (en) | 1998-01-23 | 2000-11-02 | Warner-Lambert Company | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
CA2322558C (en) | 1998-05-26 | 2006-04-11 | Warner-Lambert Company | Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
AUPP396998A0 (en) | 1998-06-09 | 1998-07-02 | University Of Melbourne, The | A method for increasing the permeability of wood |
KR100697734B1 (ko) | 1998-10-16 | 2007-03-22 | 워너-램버트 캄파니 엘엘씨 | 조증 및 양극성 장애 치료용 제약 조성물 |
WO2000031020A1 (en) | 1998-11-25 | 2000-06-02 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
IL145763A0 (en) | 1999-04-08 | 2002-07-25 | Warner Lambert Co | Method for the treatment of incontinence |
US6992109B1 (en) | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
ES2287021T3 (es) | 1999-07-22 | 2007-12-16 | University Of Rochester | Metodo para el tratamiento de sintomas de variacines hormonales que incluyen el fogaje. |
GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
SK17922002A3 (sk) | 2000-06-26 | 2003-11-04 | Warner-Lambert Company | Obdoby gabapentínu na liečenie porúch spánku |
GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
AU2002211863A1 (en) | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
US7144877B2 (en) | 2000-10-06 | 2006-12-05 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
EP1361847A2 (en) | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
WO2002042414A2 (en) | 2000-11-17 | 2002-05-30 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
JP2002346303A (ja) | 2001-05-28 | 2002-12-03 | Mitsubishi Chemicals Corp | 晶析方法 |
JP2002355501A (ja) | 2001-05-30 | 2002-12-10 | Sumitomo Chem Co Ltd | 滴下晶析方法 |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
KR20040016882A (ko) | 2001-06-11 | 2004-02-25 | 제노포트 인코포레이티드 | 감소된 독성을 가진 gaba 유사체 프로드러그의 구강투여용 투여 형태물 |
US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
MXPA05010515A (es) | 2003-03-31 | 2006-03-10 | Xenoport Inc | Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. |
US6816787B2 (en) | 2003-03-31 | 2004-11-09 | Schlumberger Technology Corporation | Generating and displaying a virtual core and a virtual plug associated with a selected piece of the virtual core |
US7662987B2 (en) | 2003-07-15 | 2010-02-16 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl compounds |
NZ545884A (en) | 2003-09-11 | 2010-01-29 | Xenoport Inc | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs |
KR101157436B1 (ko) | 2003-09-17 | 2012-07-05 | 제노포트 인코포레이티드 | Gaba 유사체의 전구약물을 이용한 하지불안 증후군의치료 또는 예방 |
ES2368916T3 (es) | 2003-10-14 | 2011-11-23 | Xenoport, Inc. | Forma cristalina de un análogo del ácido gamma-aminobutírico. |
CN102702065A (zh) | 2003-12-30 | 2012-10-03 | 什诺波特有限公司 | 酰氧基烃基氨基甲酸酯前药及其中间体的合成 |
US20050209319A1 (en) | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
CA2584338C (en) | 2004-11-04 | 2013-08-06 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
WO2008060572A1 (en) | 2006-11-14 | 2008-05-22 | Xenoport, Inc. | Use of gabapentin and pregabalin prodrugs for treating tinnitus |
WO2008073257A1 (en) | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
-
2004
- 2004-10-14 ES ES04795177T patent/ES2368916T3/es active Active
- 2004-10-14 MX MXPA06004088A patent/MXPA06004088A/es active IP Right Grant
- 2004-10-14 AU AU2004282192A patent/AU2004282192B2/en not_active Ceased
- 2004-10-14 JP JP2006535673A patent/JP4308263B2/ja active Active
- 2004-10-14 US US10/966,507 patent/US8026279B2/en active Active
- 2004-10-14 EP EP04795177A patent/EP1677767B1/en active Active
- 2004-10-14 SI SI200431753T patent/SI1677767T1/sl unknown
- 2004-10-14 KR KR1020067007286A patent/KR101096480B1/ko active IP Right Grant
- 2004-10-14 DK DK04795177.7T patent/DK1677767T3/da active
- 2004-10-14 PT PT04795177T patent/PT1677767E/pt unknown
- 2004-10-14 PL PL04795177T patent/PL1677767T3/pl unknown
- 2004-10-14 CA CA2541752A patent/CA2541752C/en active Active
- 2004-10-14 SG SG200807649-9A patent/SG147437A1/en unknown
- 2004-10-14 WO PCT/US2004/033979 patent/WO2005037784A2/en active Application Filing
- 2004-10-14 RU RU2006116470/04A patent/RU2412162C2/ru not_active IP Right Cessation
- 2004-10-14 AT AT04795177T patent/ATE516801T1/de active
- 2004-10-14 NZ NZ546381A patent/NZ546381A/en not_active IP Right Cessation
- 2004-10-14 CN CN200480030148.4A patent/CN1867322B/zh not_active Expired - Fee Related
- 2004-10-14 BR BRPI0415288A patent/BRPI0415288B8/pt active IP Right Grant
-
2006
- 2006-03-27 IL IL174600A patent/IL174600A/en active IP Right Grant
- 2006-04-03 ZA ZA2006/02722A patent/ZA200602722B/en unknown
- 2006-05-11 NO NO20062112A patent/NO338275B1/no not_active IP Right Cessation
- 2006-11-16 HK HK06112593.0A patent/HK1090850A1/xx not_active IP Right Cessation
-
2008
- 2008-12-22 JP JP2008325914A patent/JP4913796B2/ja active Active
-
2009
- 2009-08-26 US US12/548,200 patent/US20100056632A1/en not_active Abandoned
- 2009-12-08 IL IL202603A patent/IL202603A/en active IP Right Grant
-
2010
- 2010-10-04 US US12/897,567 patent/US20110021628A1/en not_active Abandoned
-
2011
- 2011-06-20 US US13/164,620 patent/US8686034B2/en active Active
-
2014
- 2014-03-12 US US14/206,893 patent/US9150503B2/en active Active
-
2015
- 2015-08-20 US US14/831,688 patent/US20150353483A1/en not_active Abandoned
-
2017
- 2017-03-13 US US15/457,191 patent/US20170183296A1/en not_active Abandoned
-
2019
- 2019-01-29 US US16/261,191 patent/US20190152900A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/741,113 patent/US20200283376A1/en not_active Abandoned
-
2021
- 2021-09-20 US US17/479,382 patent/US20220251031A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0415288B8 (pt) | composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino | |
DK2275401T3 (da) | Krystallin 1{[(alpha-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexan-eddikesyre | |
MY149181A (en) | Isoxazoline derivative and preparation process thereof | |
GEP20105082B (en) | (biphenyl) carboxylic acids and derivatives thereof | |
EA200700096A1 (ru) | Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии | |
AU2003287699A1 (en) | Production of pharmaceutically active proteins in sprouted seedlings | |
UA95253C2 (ru) | Соединения аналога камптотецина, способ их получения и фармацевтическая композиция, которая их содержит | |
WO2006014429A3 (en) | Cidofovir peptide conjugates as prodrugs | |
EA200401515A1 (ru) | Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а | |
WO2004108894A3 (en) | Methods and compositions for amino acid production | |
ATE528301T1 (de) | Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen | |
HK1079764A1 (en) | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | |
WO2008023003A8 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
WO2007015918A3 (en) | Novel biologically active peptides and their new uses | |
UA87152C2 (ru) | Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения | |
AU2003245033A1 (en) | An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation | |
HUP0401526A2 (en) | Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use | |
MX2010005597A (es) | Péptidos inmunoreguladores novedosos, composiciones y usos de los mismos. | |
WO2005105832A3 (en) | Biologically active peptide vapeehptllteaplnpk derivatives | |
AU2003267393A1 (en) | Oral care compositions comprising ascorbic acid derivative | |
ATE505193T1 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
WO2007093608A8 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
ATE344800T1 (de) | Substituierte [1,4öbenzodioxin[2,3-eöisoindol- derivaten, ihr verfahren zur herstellung und ihre pharmazeutische zusammensetzungen | |
UA95254C2 (ru) | Соединения аналога камптотецина, способ их получения и фармацевтическая композиция, которая их содержит | |
ZA200707471B (en) | Novel derivatives of phosphinic amino acids, preparation method thereof and pharmaceutical compositions containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA:INT.CI.A61K 9/20, A61K 9/22, A61K 9/26, C07C 271/22, A61P 25/02 Ipc: A61K 9/20 (2011.01), A61K 9/22 (2011.01), A61K 9/2 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |